Global Healthcare Company
Leading Innovative Precision Medicines
for Unmet Medical Needs
Global Healthcare Company
Leading Innovative Precision Medicines
for Unmet Medical Needs
Our Key
Therapeutic
Areas
Strategic R&D investments
for innovative pharmaceutical development
PRESS RELEASE
-
[AACR] Dong-A ST and Aptis present 9 anticancer candidates, including ADCs
2026.03.31 Dong-A ST announced on March 25 that, in collaboration with its ADC-specialized subsidiary AbTis, it will present a total of nine anticancer research findings at the American Association for Cancer Research (AACR 2026), scheduled to take place in San Diego, USA, from April 17 to 22 (local time).At AACR 2026, Dong-A ST plans to present preclinical anticancer research outcomes encompassing diverse mechanisms of action, including a PARP7 inhibitor under in-house development, an epidermal growth factor receptor (EGFR)-targeted protein degrader (TPD) co-developed with HK inno.N, and a bispecific ADC being co-developed with AbTis.Regarding PARP7 inhibitors, two poster presentations are scheduled. These include a novel PARP7 inhibitor designed to induce immune activation and inhibit tumor growth, as well as a PARP7 inhibitor with a dual mechanism of action demonstrating potent antitumor efficacy.Dong-A ST emphasized that preclinical studies have demonstrated that its novel PARP7 inhibitor candidates under development exert potent anticancer effects by concurrently inducing immune activation and suppressing tumor growth. The company further noted that one such candidate showed strong efficacy as a monotherapy and achieved complete remission (CR) when used in combination with anti-PD-1 antibodies or standard chemotherapy.In addition, Dong-A ST will present two poster sessions on EGFR-targeted TPD co-developed with HK inno.N. These include data on the antitumor activity and safety of a mutation-selective EGFR degrader (SC3613) targeting patients with EGFR-mutated non-small cell lung cancer (NSCLC) who are resistant to tyrosine kinase inhibitors (TKIs), as well as an allosteric EGFR degrader (SC3499) designed to overcome resistance to Tagrisso(osimertinib).In preclinical studies, SC3613 selectively degraded mutant EGFR, inducing immune activation alongside potent tumor suppression, and demonstrated a significantly reduced incidence of dermatologic adverse events with improved tolerability compared to osimertinib. In addition, SC3499, based on its high specificity for selectively degrading mutant EGFR, exhibited potent anticancer activity by maintaining efficacy against a range of resistance-associated mutations to osimertinib, even with just once-daily oral administration.Five poster presentations will address dual-antibody ADC anticancer candidates being co-developed with AbTis. Specifically, these include the evaluation of immune-mediated antitumor activity and potential for combination with immunotherapies for ‘DA-3501’ (development code), a CLDN-18.2-targeted ADC;bispecific antibody ADCs targeting NECTIN-4 and PD-L1, designed to integrate immune checkpoint inhibition with targeted cytotoxicity for urothelial carcinoma and lung squamous cell carcinoma; approaches to overcoming tumor heterogeneity in gastric cancer using eKiH-based CLDN18.2 and human epidermal growth factor receptor 2 (HER2) bispecific ADCs; strategies to overcome resistance in solid tumors through eKiH-based HER2 and AXL bispecific ADCs; and enhanced targeting of heterogeneous tumors via bispecific ADCs utilizing an improved heteromerization platform and precision payload conjugation technologies.According to Dong-A ST, preclinical studies demonstrated that DA-3501 (AT-211) exhibited potent immune-mediated antitumor activity in a gastric cancer patient model resistant to existing antibody therapies. Furthermore, a bispecific ADC targeting NECTIN4 and PD-L1, developed using the company’s proprietary bispecific ADC platform, showed potential to overcome the limitations associated with conventional combinations of antibodies and immune checkpoint inhibitors.In addition, bispecific ADCs targeting CLDN18.2 and HER2, as well as HER2 and AXL, demonstrated potential to address challenges related to therapeutic resistance and target heterogeneity. The bispecific ADC platform developed by Dong-A ST using AbTis’s ‘Abclick’ platform enables the simultaneous targeting of clinically relevant antigen combinations, thereby achieving more potent and sustained antitumor effects compared to single-target ADCs.Through this presentation, Dong-A ST and AbTis aim to highlight their research capabilities and platform competitiveness in the field of anticancer therapeutics on the global stage, while actively pursuing diverse partnership opportunities. "This presentation at AACR will serve as an opportunity to demonstrate our research capabilities globally, based on our anticancer pipelines with diverse mechanisms and precision-targeted therapy strategies. Through our collaboration with AbTis, we will continue to expand our portfolio of next-generation anticancer drugs, including bispecific ADCs,"a Dong-A ST official said.Source : [AACR] Dong-A ST and Aptis present 9 anticancer candidates, including ADCs < ENGLISH NEWS < 기사본문 - 더바이오
2026-05-18
-
Dong-A ST secures Canadian approval for Stelara biosimilar ‘Imuldosa’
2026.01.29 Dong-A ST announced on January 28 that its Stelara biosimilar, ‘IMULDOSA’ (development code DMB-3115, ustekinumab), has obtained marketing approval from Health Canada.IMULDOSA is a biosimilar to Stelara, originally developed by the multinational pharmaceutical company Johnson & Johnson Innovative Medicine (formerly Janssen). The reference product has generated global sales of approximately USD 21.552 billion (based on 2024 estimates from IQVIA).IMULDOSA is actively advancing its global market expansion, having been launched in 19 countries, including the United States, Germany, the United Kingdom, and Ireland. In addition, the product has obtained marketing approval across Middle East and North Africa (MENA) markets, including Saudi Arabia, Qatar, and the United Arab Emirates."The marketing approval granted in Canada once again validates IMULDOSA's competitiveness on the global stage. Through close collaboration with our global partners, we will continue to ensure a stable supply and advance commercialization efforts in key international markets," a Dong-A ST official said.IMULDOSA was co-developed by Dong-A Socio Holdings and Meiji Seika Pharma beginning in 2013. To facilitate efficient execution of the global development and commercialization strategy, the associated rights were transferred to Dong-A ST in July 2020. Subsequently, in July 2021, a global licensing agreement for IMULDOSA was concluded with the multinational pharmaceutical company Intas Pharmaceuticals. Under this agreement, Intas Pharmaceuticals is commercializing IMULDOSA worldwide through its affiliates, including Accord BioPharma in the U.S. and Accord Healthcare in Europe, the United Kingdom, and Canada.Source : Dong-A ST secures Canadian approval for Stelara biosimilar ‘Imuldosa’ < ENGLISH NEWS < 기사본문 - 더바이오
2026-05-18
-
Dong-A ST, Accord launch Stelara biosimilar Imuldosa in US
2025.08.19 Korea’s Dong-A ST has launched its Stelara (ustekinumab) biosimilar Imuldosa in the United States through partners Intas Pharmaceuticals and Accord Biopharma, the company said Tuesday.The drug, developed with Japan’s Meiji Seika Pharma, is approved for plaque psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis. Janssen’s Stelara generated $21.55 billion in global sales in 2024, according to IQVIA.Imuldosa is already available in 14 countries, including Germany, the U.K. and Spain, and has marketing approval in Saudi Arabia, Qatar and the UAE.Dong-A ST transferred development and commercialization rights for the project in 2020 and in 2021 signed a global out-licensing deal with Intas, which is rolling out the biosimilar through its Accord subsidiaries in the U.S., Europe, the U.K. and Canada. Source : KBR(https://www.koreabiomed.com)
2025-11-14
LOCATION
Please check our location information
- Corporate Headquarters
-
64, Cheonho-daero, Dongdaemun-gu, Seoul
Tel. 02-920-8111
- Research Headquarters
(Yong-in) -
21, Geumhwa-ro 105beon-gil, Giheung-gu, Yongin-si, Gyeonggi-do
Tel. 031-280-1400
- Research Headquarters
(Song-do) -
45, Jisikgiban-ro, Yeonsu-gu, Incheon
Tel. 032-610-0300